key: cord-0722389-twhzix2b authors: Pasomsub, Ekawat; Watcharananan, Siriorn P.; Boonyawat, Kochawan; Janchompoo, Pareena; Wongtabtim, Garanyuta; Suksuwan, Worramin; Sungkanuparph, Somnuek; Phuphuakrat, Angsana title: Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease-2019 (COVID-19): a cross-sectional study date: 2020-05-15 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2020.05.001 sha: 72672e348a82ea86cf201634c7440dd5cd788ef7 doc_id: 722389 cord_uid: twhzix2b OBJECTIVES: Amid the increasing number of pandemic coronavirus disease 2019 (COVID-19) cases, there is a need for a quick and easy method to obtain a non-invasive sample for the detection of this novel coronavirus 2019 (SARS-CoV-2). We aimed to investigate the potential use of saliva samples as a non-invasive tool for the diagnosis of COVID-19. METHODS: From 27 March to 4 April, 2020, we prospectively collected saliva samples and a standard nasopharyngeal and throat swab in persons seeking care at an acute respiratory infection clinic in a university hospital during the outbreak of COVID-19. Real-time polymerase chain reaction (RT-PCR) was performed, and the results of the two specimens were compared. RESULTS: Two-hundred pairs of the samples were collected. Sixty-nine (34.5%) patients were male, and the median (interquartile) age was 36 (28-48) years. Using nasopharyngeal and throat swab RT-PCR as the reference standard, the prevalence of COVID-19 diagnosed by nasopharyngeal and throat swab RT-PCR was 9.5%. The sensitivity and specificity of the saliva sample RT-PCR were 84.2% [95% confidence interval (CI) 60.4%-96.6%], and 98.9% (95% CI 96.1%-99.9%), respectively. An analysis of the agreement between the two specimens demonstrated 97.5% observed agreement (kappa coefficient 0.851, 95% CI 0.723-0.979; p <0.001). CONCLUSIONS: Saliva might be an alternative specimen for the diagnosis of COVID-19. The collection is non-invasive, and non-aerosol generating. This method could facilitate the diagnosis of the disease, given the simplicity of specimen collection and good diagnostic performance. Since December 2019, the outbreak of coronavirus disease 2019 (COVID-19), caused 53 by the novel coronavirus 2019 (SARS-CoV-2) has emerged in Hubei Province of China and 54 has spread to other parts of the world [1, 2] . The number of cases has been increasing rapidly, 55 with a case-fatality rate of 2.3% [3] . 56 Detection of SARS-CoV-2 in patient specimens is the first crucial step for the 57 guidance of treatment, effective infection control in the hospital and control of infection in 58 the community. Screening of infection in suspected cases with a nucleic acid amplification 59 test (NAAT), such as real-time polymerase chain reaction (RT-PCR), in respiratory 60 specimens, is recommended by the World Health Organization [4] . However, the collection 61 of nasopharyngeal and/or oropharyngeal swab specimens is a relatively invasive method and 62 the procedure might put healthcare workers at higher risk for disease transmission during 63 patients' gag reflex, cough, or sneezing. 64 The genome of SARS-CoV-2 is closely related to that of severe acute respiratory Table 1 . The prevalence of COVID-19 diagnosed by nasopharyngeal and throat 138 swab RT-PCR, and saliva RT-PCR in this study were 9.5% and 9.0%, respectively. 139 Among 19 patients diagnosed with COVID-19 by nasopharyngeal swab RT-PCR, the 140 median age was 33 (26-44) years. Fever as defined by temperature ≥37.5°C was presented in 141 3 (15.8%) patients. The mean+SD temperature was 37.0+0.5°C and the median (IQR) onset 142 of symptoms prior to the test was 3 (2-11) days. Common symptoms at presentation were 143 cough (11, 57.9%), dyspnoea (9, 47.4%), and runny nose (5, 26.3%). When compared with 144 181 patients with negative nasopharyngeal and throat swab RT-PCR, only a sore throat at 145 presentation was significantly lower in the COVID-19 patients. Other characteristics, 146 symptoms at presentation, and risk factors were not significantly different (Table 1) . 147 To determine the diagnostic test performance of RT-PCR of the saliva, RT-PCR 148 results of the nasopharyngeal and throat swabs were used as the reference standard. an early morning saliva was collected after coughing up by clearing the throat. In our study, a 167 saliva sample was the patient's self-generated, without a need for coughing up. This non-168 invasive procedure of saliva collection might be less aerosol-generating and might reduce the 169 risk of infection for health care workers working in the clinic. Although one might argue that 170 the collected specimens were possibly mixed between saliva and sputum, the chance of 171 patient's coughing up phlegm is rather low, as a recent study showed that dry cough was the 172 most common symptom presented in approximately 80% of patients at the onset of the illness 173 [14] . 174 A familial cluster of 218 pneumonia associated with the 2019 novel coronavirus indicating person-to-person 219 transmission: a study of a family cluster Clinical features of patients 221 infected with 2019 novel coronavirus in Wuhan, China Clinical characteristics of 223 coronavirus disease 2019 in China World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-225 nCoV) in suspected human cases 2020 Evolution of the novel coronavirus 229 from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human 230 transmission SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically 233 proven protease inhibitor Salivary glands: potential reservoirs for COVID-19 235 asymptomatic infection Epithelial cells lining salivary 237 gland ducts are early target cells of severe acute respiratory syndrome coronavirus 238 infection in the upper respiratory tracts of rhesus macaques Detection of SARS-240 associated coronavirus in throat wash and saliva in early diagnosis Temporal profiles of 243 viral load in posterior oropharyngeal saliva samples and serum antibody responses 244 during infection by SARS-CoV-2: an observational cohort study Laboratory diagnosis of emerging human coronavirus 247 infections -the state of the art Interrater reliability: the kappa statistic Consistent 251 detection of 2019 novel coronavirus in saliva Clinical characteristics of 254 145 patients with corona virus disease 2019 (COVID-19 Detection of SARS-CoV-2 in 257 different types of clinical specimens Presumed asymptomatic carrier 259 transmission of COVID-19 Characteristics of and important lessons from the coronavirus 261 disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from 262 the Chinese Center for Disease Control and Prevention Although testing of saliva samples might provide an advantage as a simple procedure, 175 a comparison of diagnostic study between saliva sample and confirmed-case bronchoalveolar 176 lavage (BAL) fluid or convalescence serum titre has not been available. A recent study that 177 detected the virus from multiple sites showed a lower test positivity rate from the nasal swab 178 (63%), as compared to the BAL fluid (93%) [15] . Therefore, a lower detection rate of SARS-179CoV-2 from saliva, as compared to BAL fluid among severe cases might be possible. Of 180 interest, two specimens had detectable SARS-CoV-2 from saliva samples, but not from 181 nasopharyngeal and throat swabs. Of these two samples, the Ct values of the ORF1ab and N 182 genes were 33.9 and 34.8, respectively in one specimen, and 36.2 and 33.7, respectively in 183 another specimen. These two cases later reported having anosmia. Therefore, the results of 184 these tests could represent a true infection. The yield of the saliva specimen as a 185 complementary diagnostic test for COVID-19 needs further study. 186The study has several strengths. We prospectively collected data on consecutive 187 patients who were at high risk of COVID-19 including those with acute respiratory symptoms 188 and having risk factors, thus minimising potential spectrum effect. In addition, all enrolled 189 patients were verified with the reference standard. As for the limitations, our study only